Keita Mori, CEO, spoke at “Miyaman’s Venture Talk vol.15: Exploring Brain Regeneration with Mitsuru Miyata and Keita Mori,” hosted by LINK-J (April 9, 2026)

Keita Mori, CEO, will be a speaker at “Regenerative Medicine EXPO” hosted by RX Japan(2026.5.21)

Keita Mori, President & CEO, participated as a speaker in the sponsored seminar at “BioJapan 2025” (October 9, 2025)

Keita Mori, CEO, will be a panelist at “US-Japan Healthcare Connection” hosted by the Japan Society of Northern California (2025.9.19)

Sawaguchi, Head of Japan Regulatory Affairs & Quality Compliance Japan, will speak at 【Regenerative Medicine Seminar 2024】“Development of Regenerative Medicine Products: Recent Trends in Regenerative Medicine and Other Related Issues” (Vol.5: Quality in Regenerative Medicine Products)” hosted by the Clinical and Translational Research Center (CTR) Keio University Hospital

MORI, President & CEO, will be a panelist at “Navigating Biopharma Innovation Across the Pacific” hosted by the U.S. Embassy and the Japan Society of Northern California on November 11

Presentation of Phase 2 STEMTRA Trial Results at The 14th World Congress on Brain Injury

Head of Regulatory Affairs Japan, Kazumi Sawaguchi, Ph.D., gave a presentation at 5th DIA Cell and Gene Therapy Products Symposium in Japan

5th DIA Cell and Gene Therapy Products Symposium in Japan
“Regenerative Medicine from Innovation to Industrialization”

December 10-11, 2020
Day 1: Industrialization of Regenerative Medicines: Basic Concepts of Reliable and Stable Quality Manufacturing
Day 2: Industrialization of Regenerative Medicines: Securing Supply Systems, Issues in Medical Settings, and Trends in Asia
Virtual Meeting (Zoom Webinar)

Since 2016, DIA Japan has been holding a regenerative medicine symposium to find the solutions of key problems faced by companies and academia using constructive discussions of each stage of the process, from research to post-marketing, between public and private sectors.

On Day 1 at the 5th DIA Cell and Gene Therapy Products Symposium in Japan, Kazumi Sawaguchi, Ph.D., Head of Regulatory Affairs Japan (Current Title: Head of Japan Regulatory Affairs and Quality Control) gave a presentation on “Challenge to Comparability Evaluation and Change Control” during Session 3: “Strategy for Comparability Study on Change Management of Cell Therapy Products and Gene Therapy Products”. Additional information about this event is available at DIA Japan.

Presentation Material

SanBio to Present at the 39th Annual J.P. Morgan Healthcare Conference

Message from Representative Director and President, Keita Mori, regarding disclosures made on December 13, 2019

次ページへ »